NVOS (Novo Integrated Sciences) Debt-to-EBITDA : -0.11 (As of May. 2024)


NVOS Novo Integrated Sciences Inc NVOS
12 GF Score
Price $0.00
View Full Analysis

What is Novo Integrated Sciences Debt-to-EBITDA?

Novo Integrated Sciences NVOS 12 Debt-to-EBITDA is -0.11 as of May. 2024. GuruFocus rates NVOS with a GF Score™ of 12/100.

Debt-to-EBITDA measures a company's ability to pay off its debt.

Novo Integrated Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in May. 2024 was $2.90 Mil. Novo Integrated Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in May. 2024 was $1.60 Mil. Novo Integrated Sciences's annualized EBITDA for the quarter that ended in May. 2024 was $-40.38 Mil. Novo Integrated Sciences's annualized Debt-to-EBITDA for the quarter that ended in May. 2024 was -0.11.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Novo Integrated Sciences's Debt-to-EBITDA or its related term are showing as below:

NVOS's Debt-to-EBITDA is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 2.22
* Ranked among companies with meaningful Debt-to-EBITDA only.

Novo Integrated Sciences  (OTCPK:NVOS) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Novo Integrated Sciences Debt-to-EBITDA Related Terms

Novo Integrated Sciences Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Novo Integrated Sciences's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novo Integrated Sciences Debt-to-EBITDA Chart

Novo Integrated Sciences Annual Data
Trend Dec14 Dec15 Dec16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -50.12 -1.32 -5.31 -0.58 -0.77

Novo Integrated Sciences Quarterly Data
Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.55 -0.53 -0.40 -1.45 -0.11

NVOS vs BACK, NHLG, FCHS: Debt-to-EBITDA Comparison

For the Medical Care Facilities subindustry, Novo Integrated Sciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Novo Integrated Sciences Debt-to-EBITDA vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Novo Integrated Sciences's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Novo Integrated Sciences's Debt-to-EBITDA falls into.


NVOS
12GF Score
Novo Integrated Sciences Inc NVOS
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novo Integrated Sciences Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Novo Integrated Sciences's Debt-to-EBITDA for the fiscal year that ended in Aug. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2.713 + 1.759) / -5.849
=-0.76

Novo Integrated Sciences's annualized Debt-to-EBITDA for the quarter that ended in May. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2.904 + 1.598) / -40.384
=-0.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (May. 2024) EBITDA data.

Frequently Asked Questions Learn more about Debt-to-EBITDA →
What does a Debt-to-EBITDA of -0.11 mean?
Novo Integrated Sciences (NVOS) has a Debt-to-EBITDA of -0.11 as of May. 2024. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Novo Integrated Sciences.
Is Novo Integrated Sciences' Debt-to-EBITDA too high?
Novo Integrated Sciences' current Debt-to-EBITDA is -0.11. Overall, Novo Integrated Sciences has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Novo Integrated Sciences' Debt-to-EBITDA compare to BACK and NHLG?
Novo Integrated Sciences' Debt-to-EBITDA of -0.11 can be compared against companies in the Healthcare Providers & Services industry. The industry median Debt-to-EBITDA is 2.22. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.22, based on 477 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Novo Integrated Sciences. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novo Integrated Sciences's current Debt-to-EBITDA is -0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novo Integrated Sciences stock overvalued right now?
Novo Integrated Sciences (NVOS) has a current Debt-to-EBITDA of -0.11. The current Debt-to-EBITDA is -0.11. Novo Integrated Sciences' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Novo Integrated Sciences (NVOS), the current Debt-to-EBITDA is -0.11 as of May. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Novo Integrated Sciences Business Description

Address 11120 NE 2nd Street, Suite 100, Bellevue, WA, USA, 98004
Novo Integrated Sciences Inc is a medical care company. It provides specialized physiotherapy, chiropractic care, occupational therapy, eldercare, laser therapeutics, massage therapy, acupuncture, neurological functions, kinesiology, and others. It has two reportable segments: healthcare services and product sales. Healthcare services generate the majority of revenue.
12GF Score

Get the complete analysis for NVOS

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price